The Sacklers tried to use Purdue's bankruptcy as a shield. It failed 5–4.
Purdue filed for Chapter 11 in 2019 with a plan to release the Sacklers from all opioid claims. In 2024 the Supreme Court blocked it, 5–4. The final $7.4 billion settlement grants the family no immunity.
Transcript
In September 2019, Purdue Pharma filed for Chapter 11. The Sackler family did not. The plan was to use Purdue's bankruptcy to release the family from all opioid claims anyway.
Option one: a bankruptcy shield, a permanent liability firewall for the family. Option two: settle, with no immunity for the family. Purdue chose the shield.
The Sacklers had withdrawn about $11 billion from Purdue before the bankruptcy. They proposed to return $4.325 billion, in exchange for a nonconsensual discharge of all opioid claims.
On June 27, 2024, the Supreme Court ruled 5 to 4 that the Bankruptcy Code does not authorize discharging claims against a nondebtor without claimant consent. The release was blocked. A final $7.4 billion settlement was confirmed on November 18, 2025. On May 1, 2026, Purdue dissolved.
All 55 attorneys general agreed to the final Purdue deal. It does not grant the Sacklers immunity from future opioid lawsuits. Purdue's operations moved to a new company, Knoa Pharma, which is barred from marketing opioids.
The Sackler plan tried to buy certainty. It got six years of litigation, a larger settlement, and no shield. One case is extreme, but the lesson travels: if your plan depends on a court accepting an unusual term, plan for the day it says no.
The records behind this video
Every figure in the video comes from this Decision Record, each with its sources.
Run this decision
The Residual Strategy Pack. “How much of your decline can the agreed explanation actually account for?” The framework, a model, a deck and the sourced cases, for running the same call on your own business. See the pack, $499 →
